Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Drugs acting on the respiratory system
Dornase alfa
Другие языки:

Dornase alfa

Подписчиков: 0, рейтинг: 0
Dornase alfa
Clinical data
Trade names Pulmozyme
AHFS/Drugs.com Monograph
MedlinePlus a694002
License data
Pregnancy
category
  • AU: B1
Routes of
administration		 Inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only / Schedule D
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.029.685
Chemical and physical data
Formula C1321H1999N339O396S9
Molar mass 29254.04 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.

Medical uses

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.

Society and culture

Legal status

Dornase alfa is an orphan drug.

Research

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.


Новое сообщение